Editorial abstract cover illustrating Private Insurance Payer Research in Saudi Arabia: CHI, Insurers and Formulary Decisions
    Market Research

    Who pays for a private prescription in Saudi Arabia? — Saudi health insurance payer research before a claim is approved

    A
    Armela BelbaGlobal Research Manager
    17 Oct 2026
    9 min
    Saudi Arabia
    Saudi ArabiaHealth InsuranceCHIDhaman FormularyMarket AccessPayer ResearchPrimary ResearchPrivate Insurance
    Share:

    A launch team that needs Saudi health insurance payer research is asking who will pay a private prescription. This page sits on healthcare market research, next to healthcare market research in Saudi Arabia and the directory of health insurers in Saudi Arabia. The Council of Health Insurance, CHI, runs the private-insurance rules. The Insurance Authority watches the insurance companies. Those are different offices. A premium total does not tell you whether a named drug will be paid.

    Two councils, two jobs

    CHI’s own law is the Cooperative Health Insurance Law, issued by Royal Decree M/10 on 12 August 1999 (Royal Decree M/10). The policy page says the Essential Benefit Package has applied from 1 October 2022 (CHI policy page). The updated package itself is dated to that same day (Essential Benefit Package). The package is the minimum cover. It is not a promise that every new medicine is included.

    The Insurance Authority is a different body. Its FAQ says it has been the authorised insurance regulator from 23 November 2023, under Council of Ministers Resolution 85 of 15 August 2023 (Insurance Authority FAQ). The Authority’s about page dates the same resolution as 28/1/1445 H (Insurance Authority). Quote each page’s date as that page prints it. Do not merge the two lines into a third date. The Ministry of Health, writing about the Authority’s stand at the Global Health Exhibition 2025, mentioned 23 licensed health writers (Ministry of Health, 2025). That is an exhibition note. It is not a list of who pays for one drug.

    A 2024 country note from the Pharmaceutical Pricing and Reimbursement Information network describes the health system and how medicines are priced (PPRI 2024). Read it for the public pricing path. Do not read it as a CHI enrolment file. The Saudi Food and Drug Authority is the marketing-authorisation authority for medicines (SFDA). Registration means the product may be sold. It does not mean a private insurer will pay. NUPCO, the National Unified Procurement Company, was founded in 2009 and is fully owned by the Public Investment Fund (NUPCO). NUPCO buys for government hospitals. A NUPCO award is not a CHI claim.

    Saudi Vision 2030’s Health Sector Transformation Program is the reform frame (Vision 2030 health programme). The programme page does not name which insurer will list a new medicine. Grand View Research and IMARC sell syndicated outlooks for Saudi healthcare and insurance. Use them as background. They are not a formulary interview.

    How many people are insured

    Keep the beneficiary notes in the order CHI published them. On 7 January 2025, CHI said more than 13 million people had private health insurance (CHI, 7 January 2025). On 27 October 2025, CHI said 14 million people had private health insurance in the third quarter of 2025 (CHI, 27 October 2025). Those are two dates. Do not average them, and do not turn either number into the number of people who will start one drug.

    Chart of CHI private-insurance beneficiaries reported for the third quarter of 2025
    On 27 October 2025, CHI said private insurance covered 14 million beneficiaries in the third quarter of 2025. An earlier note, on 7 January 2025, said more than 13 million. Those are two dates, not one demand figure.

    CHI’s research library lists a beneficiaries report last updated on 24 September 2025 (CHI research library). Its statistics page, with views of insured people and Nafis claims, was updated on 10 August 2025 (CHI statistics). Nafis, or NPHIES, is the exchange those claims move through. Use the library date and the statistics date as freshness checks. They are not a second headcount.

    The resident population is a different file again. The General Authority for Statistics put mid-2024 residents at 35.3 million (GASTAT, 2024). The national platform prints the same estimate as 35,300,280 (my.gov.sa). That is one population figure from two pages, not two populations. It is also larger than the insured count, because not every resident is in private insurance. GASTAT counted 516 hospitals in 2024 (GASTAT hospitals, 2024). A hospital count is not an insured-patient count.

    What the drug list is

    The CHI Dhaman formulary is the Council’s drug list. CHI describes it as an open list of essential medicines that the SFDA has registered (CHI Dhaman formulary). An Arabic page of the same list is published as دليل ضمان للأدوية (Arabic Dhaman page). Open, here, means the list is built from registered medicines. It does not mean every registered medicine is paid at every hospital without a further rule.

    CHI also runs an Insurance Drug Formulary programme. Requests to add a product go to IDF@chi.gov.sa (CHI addition requests). A user guide for the Daman Drug Formulary master spreadsheet is dated 24 March 2025 (CHI spreadsheet guide, 24 March 2025). Daman, in this label, is the CHI spelling of the same formulary programme. Read the guide for how the sheet is organised. Do not treat a row in the sheet as proof that a claim was paid last month.

    An insurer can still have its own medical rules after a drug is on the CHI list. Bupa Arabia’s financial statements for the year ended 31 December 2024 report medical-only gross written premium (Bupa Arabia, 2024). That line tells you Bupa reports medical business on its own. It does not tell you Bupa’s rule for a named molecule. Ask the insurer. The CHI list, the insurer’s rule and the hospital committee are three questions.

    Three published private-access layers: CHI Dhaman formulary, insurer medical policy, and hospital Pharmacy and Therapeutics
    Three private-access layers a 2026 brief must keep separate: the CHI Dhaman / Insurance Drug Formulary, each insurer’s medical policy, and hospital Pharmacy and Therapeutics. They are not one committee.

    What happens when a claim is sent

    NPHIES is the unified health-insurance exchange CHI runs with the National Center for Health Information (NPHIES). CHI also publishes an Arabic page for the same programme, منصة نفيس (Arabic NPHIES page). The implementation guide covers eligibility, prior authorisation and claims (NPHIES guide). Prior authorisation means the insurer is asked to approve a treatment before it is given. A hospital that wants CHI accreditation has to connect to NPHIES (CHI accreditation).

    A failed claim can fail at eligibility, at authorisation, or at payment. The guide names those steps. It does not say which step stops a particular drug. That is what payer interviews are for. Ask which code the hospital sends, who answers, and how long the answer takes. Do not infer the answer from a premium table.

    Premiums are not prescriptions

    The Insurance Authority’s Saudi Insurance Market Report 2024 puts health gross written premium at SAR 42,248.5 million (Insurance Authority, 2024 report). Gross written premium is the premium insurers recorded. It is not the amount paid to hospitals for one medicine, and it is not a patient count. The Authority’s news note of 7 May 2025 is the public pointer to that report (Insurance Authority, 7 May 2025). The annual-publications page lists both the 2025 and the 2024 market reports (Insurance Authority publications). Use the report that matches the year you cite.

    Bar chart of Saudi health-insurance gross written premiums 2020 to 2024 from the Insurance Authority
    The Insurance Authority’s 2024 market report puts health gross written premium at SAR 42,248.5 million. That is the health line in that report. It is not a vote on one drug.

    On 31 July 2026 the Saudi Press Agency reported the Insurance Authority saying gross written premium exceeded SAR 84 billion (Saudi Press Agency, 31 July 2026). The agency note does not label that 84 billion as health only. Do not subtract it from the 2024 health figure and call the gap a forecast. They are different statements, on different dates.

    Insurance Authority market report as a structure file, separate from a hospital formulary vote
    The Insurance Authority’s 2024 report describes the insurance market. It is not a hospital formulary vote and it is not a count of patients on one drug.

    A model that starts from 14 million beneficiaries, or from SAR 42,248.5 million, and ends at “patients on our drug” has skipped the list, the insurer rule and the claim. Those three are the study.

    Questions to put in the brief

    Write the decision in one line before you pick a sample. The decision might be a Dhaman addition, a change to an insurer’s medical rule, or a listing at a hospital that bills CHI.

    Checklist of seven Saudi health insurance payer research workstreams for a CHI or insurer formulary brief
    Seven workstreams for Saudi health insurance payer research: insured population, Dhaman listing, insurer medical policy, benefit tier, NPHIES friction, copay and substitution, and share of treated privately insured patients.
    • Which people. Say whether you mean the January 2025 note, the October 2025 note, or both. Do not call either note the whole population of 35.3 million.
    • Which list. Ask if the scientific name is on the CHI Dhaman formulary, and which edition of the spreadsheet the payer is using.
    • Which insurer rule. A place on the CHI list is not the same as a Bupa medical rule, or any other writer’s rule. The exhibition note’s 23 writers are not that rule.
    • Which claim step. Ask where the NPHIES transaction stops: eligibility, prior authorisation, or payment.
    • Which hospital. The 516 hospitals are not the sampling frame. Name the hospitals that bill the insurers in the brief.
    • Which public path you will leave out. NUPCO and SFDA registration are real gates. They are not a private claim.

    Report the result as a share of treated patients who are privately insured, at named hospitals. Ask for Arabic and English instruments. Ask which CHI page and which date the agency will quote.

    How to brief BioNixus

    BioNixus is a primary market research firm for pharmaceutical, medical device and healthcare companies. It was founded in 2012. Custom studies are usually priced at $10k–$60k. The firm has 40 client reviews on its public profiles. The line “Guaranteed in writing” covers the agreed scope and timeline. It does not cover what the interviews will find.

    Leadership offices are in Sheridan, Wyoming, London, and Sheikh Zayed, Giza. Field offices are in Dubai, Al Khobar, and Salmiya, Kuwait. São Paulo is a field office for LATAM.

    To brief a payer study, use the contact form or email admin@bionixus.com. Say which insurer, which list and which decision the study has to answer.

    References

    1. CHI. 14 million private-insurance beneficiaries in Q3 2025. News, 27 October 2025. Source (accessed 17 October 2026).
    2. CHI. More than 13 million private-insurance beneficiaries. News, 7 January 2025. Source (accessed 17 October 2026).
    3. CHI. CHI Drug Formulary (Dhaman). Open SFDA-registered essential-drug list. Source (accessed 17 October 2026).
    4. CHI. دليل ضمان للأدوية. Arabic Dhaman formulary page. Source (accessed 17 October 2026).
    5. CHI. Insurance Drug Formulary (IDF) programme. Addition requests to IDF@chi.gov.sa. Source (accessed 17 October 2026).
    6. CHI. Daman Drug Formulary Master Excel Sheet User Guide, 24 March 2025. Source (accessed 17 October 2026).
    7. CHI. Cooperative Health Insurance Policy page. Essential Benefit Package from 1 October 2022. Source (accessed 17 October 2026).
    8. CHI. Updated Essential Benefit Package, effective 1 October 2022. Source (accessed 17 October 2026).
    9. CHI. Cooperative Health Insurance Law. Royal Decree M/10, 12 August 1999. Source (accessed 17 October 2026).
    10. CHI. Request for accreditation of a health-service provider. NPHIES integration required. Source (accessed 17 October 2026).
    11. CHI. NPHIES. Unified health-insurance exchange with the National Center for Health Information. Source (accessed 17 October 2026).
    12. CHI. منصة نفيس. Arabic NPHIES programme page. Source (accessed 17 October 2026).
    13. NPHIES. Healthcare Financial Services Implementation Guide. Eligibility, prior authorisation, claims. Source (accessed 17 October 2026).
    14. CHI. Research Library. Beneficiaries Report last updated 24 September 2025. Source (accessed 17 October 2026).
    15. CHI. Statistics & Indicators. Insured-individual and Nafis-claim views. Updated 10 August 2025. Source (accessed 17 October 2026).
    16. Insurance Authority. The Saudi Insurance Market Report 2024. Health GWP SAR 42,248.5 million. Source (accessed 17 October 2026).
    17. IA. Insurance Authority Issues the Saudi Insurance Market Report of 2024. News, 7 May 2025. Source (accessed 17 October 2026).
    18. IA. Annual publications. Lists the 2025 and 2024 insurance-market reports. Source (accessed 17 October 2026).
    19. Saudi Press Agency. Insurance Authority: GWP exceed SAR 84 billion. 31 July 2026. Source (accessed 17 October 2026).
    20. IA. FAQs. Authorised insurance regulator from 23 November 2023 (CM Resolution 85, 15 August 2023). Source (accessed 17 October 2026).
    21. IA. About the Authority. Established by Council of Ministers Resolution No. 85, 28/1/1445 H. Source (accessed 17 October 2026).
    22. Ministry of Health. Insurance Authority at the Global Health Exhibition 2025. 23 licensed health writers. Source (accessed 17 October 2026).
    23. Bupa Arabia. Consolidated financial statements, year ended 31 December 2024. Medical-only GWP. Source (accessed 17 October 2026).
    24. PPRI. Healthcare system and pharmaceutical pricing in Saudi Arabia (2024). Source (accessed 17 October 2026).
    25. GASTAT. Population Estimates Statistics 2024. Mid-2024 residents: 35.3 million. Source (accessed 17 October 2026).
    26. National Platform (my.gov.sa). Reports and Statistics. Population in 2024: 35,300,280. Source (accessed 17 October 2026).
    27. GASTAT. Healthcare Establishments and Workforce Statistics 2024. 516 hospitals. Source (accessed 17 October 2026).
    28. NUPCO. Overview. Founded 2009; fully owned by the Public Investment Fund. Source (accessed 17 October 2026).
    29. Saudi Food and Drug Authority. Home. Marketing-authorisation authority for medicines. Source (accessed 17 October 2026).
    30. Saudi Vision 2030. Health Sector Transformation Program. Source (accessed 17 October 2026).
    31. Grand View Research. Saudi Arabia healthcare / pharmaceutical outlook pages. Syndicated sizing. (accessed 17 October 2026).
    32. IMARC Group. Saudi Arabia healthcare / insurance market report pages. Syndicated outlooks. (accessed 17 October 2026).

    Explore related research

    For deeper regional insight, explore our healthcare market research framework and country coverage.

    Explore BioNixus capabilities & hubs

    Directory of every indexed marketing destination — GCC and MENA research pages, localized hubs, methodologies, pharmaceutical directories, reports, global websites, insights, case studies, methodology, and Arabic coverage. Prefer this index over generic “related” lists for full-site context.

    12 groups · 265 URLs

    Full structured sitemap
    Home & language hubsLocalized entry points for BioNixus.5
    Company, trust & methodologyAbout, contact, compliance, and how we work.28
    Core servicesQuantitative, qualitative, access, intelligence, trials, KOL.3
    Healthcare market research hubCountries, cities, therapy areas, and research modules.57
    GCC, MENA & specialty programsPillar landings, alternatives, and deep-dive reports.36
    Pharmaceutical company directoriesCountry-level industry snapshots.9
    Healthcare & devices market reportsGCC and country medical market briefs.1
    Blog & insightsEditorial briefs, guides, and regional analysis.80
    Case studiesSelected client evidence and programme outcomes.5
    Portfolio & conferenceStrategic portfolio deck and event pages.2
    Localized pagesMarket access, contacts, and market research by locale.6
    Additional pagesSupporting URLs and tooling.33

    FAQFrequently asked questions

    What is Saudi health insurance payer research?
    It is commissioned research on which private insurer will pay for a medicine, on which list, and after which approval. A premium total and a beneficiary count do not answer that.
    How many people have private health insurance in Saudi Arabia?
    CHI said more than 13 million on 7 January 2025, and 14 million for the third quarter of 2025 on 27 October 2025. Those are two official notes. They are not the 35.3 million residents, and they are not patients on one drug.
    What is the CHI Dhaman formulary?
    It is the Council of Health Insurance drug list, described as an open list of essential medicines the Saudi Food and Drug Authority has registered. A place on the list is not the same as a paid claim.
    How do you add a medicine to the CHI list?
    CHI’s Insurance Drug Formulary programme takes addition requests at IDF@chi.gov.sa. A spreadsheet guide is dated 24 March 2025. Sending a request is not proof the claim will be paid.
    Is CHI the same as the Insurance Authority?
    No. CHI runs the private health-insurance benefits and the Dhaman list. The Insurance Authority has been the insurance regulator since 23 November 2023 and publishes market premiums, including health gross written premium of SAR 42,248.5 million in its 2024 report.
    Does a drug on Dhaman get paid automatically?
    The sources here do not say that. The Essential Benefit Package dates from 1 October 2022. Claims still move through NPHIES, which covers eligibility, prior authorisation and payment. Ask the named insurer what rule it still applies.
    What does a BioNixus study cost, and what is guaranteed?
    Custom studies are usually $10k–$60k. Guaranteed in writing covers the agreed scope and timeline. It does not cover what the interviews will find. The firm has 40 client reviews on its public profiles.

    Expert Consultation

    Planning Saudi health insurance payer research for a CHI or insurer listing?

    Tell us the payer decision you need to make. BioNixus scopes the study around that decision. Custom work is usually $10k–$60k.

    Talk to BioNixus
    A

    Research Author

    Armela Belba

    Global Research Manager

    Related Articles

    Saudi hematology diagnostics reports count analyzers. Pharma still needs the ward-level brand cut.
    Healthcare Market Research
    Saudi Arabia15 Nov 2026

    Saudi hematology diagnostics reports count analyzers. Pharma still needs the ward-level brand cut.

    Saudi hematology diagnostics reports size analyzers and reagents. They do not show which ward is moving medicine share. Here is the cut primary research still has to make.

    Read article
    Syndicated Saudi diabetes numbers size the category. They still miss which hospital is switching.
    Healthcare Market Research
    Saudi Arabia15 Nov 2026

    Syndicated Saudi diabetes numbers size the category. They still miss which hospital is switching.

    Syndicated Saudi diabetes reports size the category. They do not show which hospital is switching. Here is what primary research still has to answer.

    Read article
    ADCAN Pharma and M42 Want to Make the UAE an Oncology Supply Hub. The First Step Is a Pack, Not a Plant
    Healthcare Market Research
    UAE11 Nov 2026

    ADCAN Pharma and M42 Want to Make the UAE an Oncology Supply Hub. The First Step Is a Pack, Not a Plant

    ADCAN Pharma and M42 signed an MoU on UAE oncology manufacturing, an ADC registration and IROS clinical trials. What is confirmed and what to research.

    Read article
    The UAE Has Cleared Lilly's Foundayo Pill for Type 2 Diabetes. The Harder Questions Start Now
    Healthcare Market Research
    UAE10 Nov 2026

    The UAE Has Cleared Lilly's Foundayo Pill for Type 2 Diabetes. The Harder Questions Start Now

    The UAE approved Lilly's oral GLP-1 Foundayo for type 2 diabetes on 6 Nov 2026. What is confirmed, what is not, and what launch teams should research.

    Read article
    AstraZeneca Brings CRISPR Gene-Editing Research to Saudi Arabia: What the KAIMRC Programme Is, and Is Not
    Healthcare Market Research
    Saudi Arabia9 Nov 2026

    AstraZeneca Brings CRISPR Gene-Editing Research to Saudi Arabia: What the KAIMRC Programme Is, and Is Not

    AstraZeneca and KAIMRC are running preclinical CRISPR research on ASL deficiency in Saudi Arabia, with training for up to 12 Saudi scientists. What is confirmed and what to research next.

    Read article

    Planning research in Saudi Arabia?

    Primary research, market access & HEOR. A 30-minute scoping call, then a costed proposal within 48 hours.

    What happens on the call

    • We pin down the decision your research has to support.
    • We check feasibility: respondent types, countries and timeline.
    • You receive a costed proposal within 48 hours of the call.